TuHURA Biosciences/$HURA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About TuHURA Biosciences
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
- Ticker
- $HURA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Tampa, United States
- Website
- www.tuhurabio.com
HURA Metrics
BasicAdvanced
$97M
-
-$0.54
-
-
Price and volume
Market cap
$97M
52-week high
$3.43
52-week low
$0.41
Average daily volume
395K
Financial strength
Current ratio
0.179
Quick ratio
0.14
Long term debt to equity
0.205
Total debt to equity
0.496
Interest coverage (TTM)
-27.68%
Profitability
EBITDA (TTM)
-30.927
Management effectiveness
Return on assets (TTM)
-58.43%
Return on equity (TTM)
-161.39%
Valuation
Price to book
5.31
Price to tangible book (TTM)
12.93
Price to free cash flow (TTM)
-2.868
Free cash flow yield (TTM)
-34.87%
Free cash flow per share (TTM)
-0.53
Growth
Earnings per share change (TTM)
-33.76%
What the Analysts think about HURA
Analyst ratings (Buy, Hold, Sell) for TuHURA Biosciences stock.
Analyst projections of the future price of TuHURA Biosciences stock.
HURA Financial Performance
Revenues and expenses
HURA Earnings Performance
Company profitability
Upcoming events
No upcoming events
HURA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.